{
    "clinical_study": {
        "@rank": "112538", 
        "arm_group": {
            "arm_group_label": "Gemcitabine + Cisplatin + Necitumumab", 
            "arm_group_type": "Experimental", 
            "description": "Necitumumab administered  intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.\nGemcitabine administered IV at 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.\nCisplatin administered IV at 75 mg/m^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see how participants with late stage lung cancer do on\n      gemcitabine-cisplatin chemotherapy plus necitumumab. The study will also see how safe the\n      drugs are in combination and to see how long the medicine stays in the body. The study will\n      last approximately 2 years."
        }, 
        "brief_title": "A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed squamous Non-small Cell Lung Cancer (NSCLC)\n\n          -  Stage IV disease at time of study entry based on American Joint Committee on Cancer\n             7th edition\n\n          -  Measurable disease at time of study entry as defined by Response Evaluation Criteria\n             in Solid Tumors (RECIST), Version 1.1\n\n        Exclusion Criteria:\n\n          -  Nonsquamous NSCLC\n\n          -  Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors,\n             or any therapies targeting the epidermal growth factor receptor (EGFR), vascular\n             endothelial growth factor (VEGF), or VEGF receptor\n\n          -  Previous chemotherapy for NSCLC\n\n          -  Major surgery or received any investigational therapy in the 4 weeks prior to study\n             enrollment\n\n          -  Chest irradiation within 12 weeks prior to randomization (except palliative\n             irradiation of bone lesions, which is allowed)\n\n          -  Brain metastases that are symptomatic or require ongoing treatment with steroids or\n             anticonvulsants (participants who have undergone previous radiotherapy for brain\n             metastases, who are now nonsymptomatic and no longer require treatment with steroids\n             or anticonvulsants, are eligible)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788566", 
            "org_study_id": "14789", 
            "secondary_id": "I4X-MC-JFCK"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemcitabine + Cisplatin + Necitumumab", 
                "description": "Administered IV", 
                "intervention_name": "Necitumumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "IMC-11F8", 
                    "LY3012211"
                ]
            }, 
            {
                "arm_group_label": "Gemcitabine + Cisplatin + Necitumumab", 
                "description": "Administered IV", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Gemzar", 
                    "LY188011"
                ]
            }, 
            {
                "arm_group_label": "Gemcitabine + Cisplatin + Necitumumab", 
                "description": "Administered IV", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Deerfield Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33442"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Farmington Hills", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48334"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3A 1A1"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75970"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durango", 
                        "country": "Mexico", 
                        "zip": "34000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "zip": "44200"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands", 
                        "zip": "4818 CK"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands", 
                        "zip": "5623 EJ"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadahonda", 
                        "country": "Spain", 
                        "zip": "28222"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41014"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "404"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "112"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France", 
                "Mexico", 
                "Netherlands", 
                "Spain", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "France: Ministry of Health", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Netherlands: Ministry of Health, Welfare and Sport", 
                "Spain: Ministry of Health", 
                "Taiwan: Department of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Measured Progressive Disease (Estimated up to 24 Months)"
        }, 
        "removed_countries": {
            "country": "Korea, Republic of"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788566"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Death from Any Cause (Estimated up to 27 Months)"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 24  Months)"
            }, 
            {
                "measure": "Number of Participants who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Participants Stops Study (Estimated up to 24  Months)"
            }, 
            {
                "measure": "Percent Change in Tumor Size (CTS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline until Measured Progressive Disease (Estimated up to 24 Months)"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 Hours Post Dose"
            }, 
            {
                "measure": "Number of Participants with Anti-Necitumumab Antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 30 Days Post Last Infusion (Estimated up to 24 Months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}